Human interferon-alpha was associated in different ways with positively (stearylamine) and negatively (phosphatidylserine) charged phosphatidylcholine multilameilar vesicles, depending on the presence or absence of a cholesterol component. Inclusion of cholesterol resulted in interferon that was significantly (P = 0.0001) more deeply internalized within the liposomes, such that detergent disruption was necessary before most of the interferon activity was expressed. Interferon was stably associated with stearylamine-containing liposomes, both with and without a cholesterol component. However, inclusion of cholesterol in the phosphatidylserine-containing liposomes was necessary for stable association of the interferon for more than 2 days at 4°C or for more than 24 h at 37°C. After intramuscular injection into mice, liposome-associated interferon in reverse-phase evaporation vesicles was retained at the local site of injection significantly longer than free interferon. Even 3 days after intramuscular injection, stearylaminecontaining liposomes with or without cholesterol resulted in local interferon levels that were comparable to the peak levels obtained 2 to 4 h after free interferon was injected. In contrast, free interferon was not detectable in the local muscles 24 h after injection of 104.6 U. Liposomes containing phosphatidylserine and cholesterol resulted in intermediate levels of local interferon retention; without a cholesterol component, phosphatidylserine-containing liposomes resulted in no increased local interferon retention compared with the results when free interferon was injected.
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Liposomes have great potential as delivery systems for therapeutic agents (1, 3, 4, 6, 16) . The use of liposomes can result in significantly altered bioavailability of a drug, in increased efficacy at lower doses, and in fewer unwanted side reactions (5, 10, 13, 14) . Since interferon is a drug that is in short supply, has some adverse side effects, and currently requires frequent injections to have a therapeutic effect, it is a good candidate for targeted administration via a liposome delivery system.
We and others have shown recently that HuIFN-a can be incorporated successfully into REVs, SUVs (2a) and MLVs (2, 2a). We extended these studies to include a comparison of interferon capture and stability in positively and negatively charged liposomes in the presence and in the absence of cholesterol.
A major goal of incorporating interferon into liposomes is to increase its bioavailabiity when it is administered in vivo. Liposomes alter the pharmacokinetics of drugs (8, 9, 11, 16) and after subcutaneous injection result in local retention of the encapsulated material (12, 15) . Since direct intralesional injection of interferon is feasible for therapy of certain tumors, we wanted to determine whether we could increase local interferon levels by injecting liposome-associated interferon. Initially, we studied the local retention of liposome-associated interferon after it was injected intramuscularly into mice. Trypsin and DOC treatments. MLVs and free interferon were treated with trypsin (1.5 mg/ml), which was followed by neutralization with soy bean trypsin inhibitor (2 mg/mg of trypsin), and with 0.4% (wt/vol) DOC, as described elsewhere (2a), after incubation for 0 to 4 days at 4°C in PBS or after incubation for 1 to 72 h at 37°C either in PBS or in 50%o BALB/c mouse serum. Liposomes were washed and pelletted again before trypsin treatment and DOC disruption, and all samples were diluted 1: 5 (vol/vol) before they were assayed for antiviral activity.
MATERIALS AND METHODS
Interferon assays. Interferon activity was determined by a microtiter assay for inhibition of cytopathic effects against vesicular stomatitis virus (19), using both human trisomy 21 cells (GM-2767; Mammalian Mutant Cell Repository, Camden, N.J.) and bovine MDBK cells.
Titers are reported as international reference units, based on National Institutes of Health human-alpha (leukocyte) interferon reference reagent G002-904-511.
Mice. BALB/c mice (6 to 8 weeks old) were obtained from Charles River Farms, North Wilmington, Mass. These mice were injected intramuscularly in both thighs with 0.05-ml portions of the REV-interferon preparations (104-6 to 104-9 interferon units per mouse) or with free interferon (104.6 U/mouse). One mouse from each group was sacrificed at the indicated times, and both thigh muscles were excised and quick frozen on dry ice. The muscles were homogenized and assayed for antiviral activity as 10o (wtlvol) suspensions.
RESULTS
Capture of HuIFN-a by MLVs and REVs. , and thus these titers were averaged over time (Fig. 1A, 2, and 3) . For the EPCIPS vesicles the titers remained stable for only 0 to 2 days at 4°C and for 1 to 24 h at 37°C; thus, only the averages of these values are shown in Fig. 1B . As Fig. 4 Fig. 3 and Table 3 ).
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Trypsin treatment had no effect on the interferon activity associated with EPC/CholI/SA MLVs ( Fig. 2A and Table 3 ) and caused only a slight reduction (0.1 to 0.3 log10) in the interferon activities associated with the other types of liposomes ( Fig. 1 and 2B) . However, the activity of free interferon was decreased by approximately 2.5 loglo after a comparable trypsin treatment (Fig. 3) . DOC Table 3 ) or on the activity offree interferon (Fig.  3 and Table 3 ).
Local retention of liposome-associated interferon in vitro. The retention of interferon at the sites of intramuscular injection in tnice was compared with and without incorporation of interferon into REVs. REVs rather than MLVs were used for the in vivo experiments since REVs resulted in higher interferon capture values (10 to 20%o of starting interferon [ on at the site of injection decreased rapidly after 4 h, such that no interferon activity was detected in the muscles 24 h after injection of 104.6 interferon units (Fig. 5A) , a finding which agreed with previous reports (7) .
In contrast, interferon associated with EPC/ Chol/PS REVs was retained at the site of injection at initially higher levels (P = 0.0001 at 24 h) than free interferon (Fig. SB) . This intramuscular retention was consistent with other reports concerning the local retention of vesicles at the sites of subcutaneous injection in mice (12, 15) . The EPC/PS REVs, however, did not result in significantly increased local retention of interferon.
The SA-containing liposomes were the most effective liposomes in local retention of interferon (Fig. 5C ). Both with and without Chol, the SA REVs resulted in significantly higher (P = 0.0001) initial muscle interferon levels, as well as retention of the interferon for significantly longer times (P = 0.0001 at 72 h) compared with free interferon.
DISCUSSION
The inclusion of high mole percentages of Chol in liposomes increases the capture and the stability of entrapment of several aqueous compounds (14, 16, 18) . Therefore, we studied the effect of Chol on liposomal capture and the resulting stability of HuIFN-a. Although inclusion of Chol in the liposomal membranes resulted in slightly higher capture values for HuIFNa by both positively (SA-containing) and negatively (PS-containing) charged MLVs, the increase was not statistically significant. However, the presence of Chol did result in increased stability of interferon associated with PS-containing liposomes.
The inclusion of Chol had an interesting effect on the apparent latency of the liposome-associated interferon. With Chol-containing liposomes, the interferon was significantly (P = 0.0001) more deeply internalized within the liposomes than in the absence of Chol, either within the lipid bilayer or in the aqueous compartments, such that DOC disruption was necessary before most of the interferon activity was expressed. This was especially apparent when the EPC/Chol/SA and EPC/SA MLVs were compared ( Fig. 2 and Table 1 ). Anderson et al. (2) obtained almost complete (99%o) latency of interferon by incorporating it into EPC/Chol/dicetylphosphate (7:1:2) MLVs. These authors concluded that the interferon was incorporated into the aqueous interstices of the liposomes and did not hydrophobically interact with the lipid bilayers. From our previous studies (2a) as well as the results discussed above, it appears that depending on the liposomal composition, interferon can be associated with liposomes in different ways. With some lipid compositions, particularly when Chol is present, the interferon is internalized more deeply within the liposomes and appears to be latent until the liposomal bilayer is disrupted. With other lipid compositions, the liposome-associated interferon is trypsin resistant; yet when it is incubated with cells, this interferon results in establishment of an antiviral state without prior disruption of the liposomes. One possible explanation is that the interferon is incorporated within the lipid bilayers of the liposomes and upon association with a cell, the interferon is transferred to the cellular receptor. However, we cannot yet rule out the possibility that a specific interaction of certain liposomes with cells (22) merely results in the release of liposome-associated interferon.
The results obtained after intramuscular injection of liposome-associated interferon look promising. Significantly longer retention of HuIFN-a at the site of injection was obtained with liposome-associated interferon than with free interferon. PS-containing liposomes had to contain Chol in order to result in increased local retention of HuIFN-a, which is consistent with the in vitro stability results. Future studies will determine whether this mode of administration of interferon results in increased efficacy after intratumor inoculations.
